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The addition of rituximab to CHOP chemotherapy may
augment tumor response but in patients with low CD4
counts, one study suggested that this benefit may be offset
by increased infectious deaths (Kaplan. Blood 2005;
106:1538). We hypothesized that the addition of rituxi-
mab to EPOCH chemotherapy could improve tumor kill,
allowing fewer cycles of treatment and therefore reducing
toxicity.
Patients received EPOCH-R (in mg/m2/d – etoposide 50,
vincristine 0.4 and doxorubicin 10 all CIV d 1–5; cyclo-
phosphamide 750 mg IV d 5; prednisone 60 po days 1–5
and rituximab 375 IV d 1,5 and G-CSF sc d 6–15) every 21
days. Prophlactic IT methotrexate was administered and
HAART was suspended during therapy. Cyclophospha-
mide was adjusted based on absolute neutrophil count
(ANC) nadir. Response was assessed by CT and FDG-PET
scan and patients received one cycle beyond CR for a min-
imum of three cycles. Characteristics of 40 enrolled
patients are: median (range) age 42 (9–60) years; IPI 3 (0–
4); ECOG PS 1 (1–4), CD4 count 222 (0–835) cells/mm3;
HIV viral load 34,766 (0–6,080000) RNA copies/mL;
male sex 35 (88%); LDH > N 27 (68%); stage IV 27 (68%)
and histology DLBCL 32 (80%) and BL 8 (20%). Of 38
evaluable patients (2NE), median (range) number of
cycles given is three (3–5) with CR/CRu in 35 (92%) and
PR in one (3%) patients.
All eight patients with Burkitt lymphoma are in continu-
ous remission. At four years median potential follow-up,
PFS and OS are 86 percent and 70 percent. For patients
with CD4 > and < 100 cells/mm3 PFS is 96 percent and 69
percent, respectively. IPI did not impact OS and PFS. Early
PET scanning (after cycle 2) had a very high negative pre-
dictive value (100%) but a low positive predictive value
(20%). One treatment-related death occurred (from com-
plications of mycobacterium avium intercellulare (MAI))
and other toxicity included fever or neutropenia on 30
percent, ANC < 500/mm3 on 40 percent, and platelets <
50,000 on 23 percent cycles. EPOCH-R was associated
with less CD4 loss – median 128 cells/mm3 (range +154
to -639) compared to EPOCH alone (median 189 cells/
mm3 (range +19 to -973). Abbreviated EPOCH-R is highly
effective with acceptable tolerability in ARL and enables
the administration of fewer treatment cycles (median 3
versus 6). Although patients with CD4 < 100/mm3 have
good tumor control with EPOCH-R with a PFS of 70 per-
cent at four years, overall survival for this group was only
31 percent due mainly to later deaths from complications
of advanced AIDS. In contrast, patients with high CD4
counts > 100/mm3 have an extremely favorable outcome
with and survival following EPOCH-R. The addition of
rituximab did not appear to contribute to infection related
complications or deaths. EPOCH-R showed excellent effi-
cacy in eight patients with BL with an OS and PFS of 100
percent. PET scanning has a high negative but low positive
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